Moreover, recent studies demonstrated that the TRM cell subset increases in responder patients with non-small cell lung cancer (NSCLC) and melanoma upon anti-PD-1 administration [44, 45]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.